Hypoadiponectinemia and Endogenous Nitric Oxide Synthase Inhibitor in Hypertension

To the Editor:

We read with great interest the article by Xing et al\(^1\) dealing with the relationship between adiponectin and vascular insulin resistance in hypertension. The results of their study demonstrated that hypoadiponectinemia induced vascular insulin resistance in young spontaneously hypertensive rats. In addition, the authors indicated that downregulation of APPL1 (an adaptor protein that interacts directly with adiponectin receptors by the phosphotyrosine-binding domain) might partially contribute to vascular insulin resistance by differentially modulating the activation of Akt-dependent nitric oxide (NO) and ERK1/2-dependent endothelin-1 pathways in vascular endothelium in spontaneously hypertensive rats. Furthermore, the authors proposed that supplementation with exogenous adiponectin may have potential therapeutic value in the prevention and alleviation of endothelial dysfunction and vascular insulin resistance in hypertension.

Current evidence indicates that adiponectin may improve NO bioavailability and restore endothelial dysfunction. In a study presented previously, we investigated the relationship between plasma adiponectin levels and plasma NO metabolites in hypertensive subjects.\(^2\) It was demonstrated that plasma adiponectin levels were significantly correlated with plasma NO metabolites.\(^2\) In the separate series of the study, we reported that reduced membrane fluidity of red blood cells was associated with hypoadiponectinemia in hypertensive subjects.\(^3\) Reduced membrane fluidity of red blood cells might cause a disturbance in the blood rheological behavior and microcirculation, which could contribute, at least in part, to the pathophysiology of circulatory disorders. It might be possible that adiponectin would be a defense against vascular complications in circulatory disorders through increased NO production.

However, it has been shown that, in an in vitro study, adiponectin significantly inhibited the tumor necrosis factor-\(\alpha\)-induced asymmetrical dimethylarginine (an endogenous NO synthase inhibitor) accumulation in both human umbilical vein endothelial cells and human coronary artery endothelial cells, which was accompanied by an increase in dimethylarginine dimethylaminohydrolase activity.\(^4\) Heilman et al\(^5\) also have reported the elevated plasma adiponectin and decreased plasma asymmetrical dimethylarginine levels in children with type 1 diabetes mellitus. In this context, it is strongly suggested that adiponectin would protect against endothelial dysfunction, at least in part, by influencing asymmetrical dimethylarginine metabolism. Therefore, we would like to know whether asymmetrical dimethylarginine might actively participate in hypoadiponectinemia-induced alterations in NO signaling and vascular insulin resistance in the study of Xing et al. It would be important to assess more precisely the relationships between adiponectin and endogenous NO synthase inhibitors and their role in the progression of endothelial dysfunction and insulin resistance in hypertension.

Disclosures

None.

Kazushi Tsuda
Cardiovascular and Metabolic Research Center
Kansai University of Health Sciences
Osaka, Japan


(Hypertension. 2013;62:e4.)

© 2013 American Heart Association, Inc.

Hypertension is available at http://hyper.ahajournals.org

DOI: 10.1161/HYPERTENSIONAHA.113.01641
Hypoadiponectinemia and Endogenous Nitric Oxide Synthase Inhibitor in Hypertension

Kazushi Tsuda

Hypertension. 2013;62:e4; originally published online June 10, 2013;
doi: 10.1161/HYPERTENSIONAHA.113.01641

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/62/2/e4

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/